The WIDE (Worldwide Initiative to Develop Everolimus) Program is a global initiative that encompasses a broad range of malignancies as well as tuberous sclerosis complex (TSC). Through this program, Novartis Oncology is conducting clinical studies of everolimus as a single agent and in combination with other anticancer treatments.
This website provides a concise overview of phase II and phase III clinical trials with everolimus (RAD001). All of these oncology trials are being conducted within the WIDE Program—and are either enrolling or will soon be enrolling participants. We hope that you will keep these clinical trials in mind when treating oncology patients who may be appropriate candidates for participation in a clinical trial.